XML 116 R49.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary Of Significant Accounting Policies (Computations Of Basic And Diluted EPS) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Earnings Per Share [Abstract]                      
Net income applicable to common shareholders $ (171,567) $ 14,865 $ 44,641 $ 65,727 $ 16,753 $ 46,016 $ 41,313 $ 25,857 $ (46,334) $ 129,939 $ (127,102)
Less: Undistributed net income allocable to participating securities                   (1,599)  
Net income (loss) applicable to common shareholders                 (46,334) 128,340 (127,102)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent                 (23,684) (95,221) 106,657
Add: Undistributed net income from discontinued operations allocable to participating securities                   1,172  
Income (Loss) from Continuing Operations Attributable to Parent, Total (99,679) 10,362 2,425 16,874 17,487 15,999 10,547 (9,315) (70,018) 34,291 (20,445)
Weighted average number of shares outstanding - basic                 104,449 104,528 103,857
Stock options, Shares                   64  
Undistributed earnings reallocated to participating securities, value                   2  
Convertible preferred stock                   40  
Convertible preferred stock, Shares                   361  
Income (loss) from continuing operations applicable to Helix common shareholders - Diluted                 (70,018) 34,333 (20,445)
Income (loss) from discontinued operations, net of tax (71,888) [1] 4,503 [1] 42,216 [1] 48,853 [1] (734) 30,017 30,766 35,172 23,684 95,221 (106,657)
Net income per common share - Diluted                 $ (46,334) $ 129,554 $ (127,102)
Weighted average number of shares outstanding, diluted, total                 104,449 104,953 103,857
[1] Our net loss in the fourth quarter of 2012 includes a $138.6 million impairment charge associated with the sale of ERT (Note 3).